Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
Sponsor: CARsgen Therapeutics Co., Ltd.
This NA trial investigates Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma and is currently ongoing. CARsgen Therapeutics Co., Ltd. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting NA
-
Jun 2018 — Jan 2021 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Not Yet Recruiting NA
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CARsgen Therapeutics Co., Ltd.
- Changhai Hospital
For direct contact, visit the study record on ClinicalTrials.gov .